OBTAINING AND ASSESSING IMMUNOGENICITY OF A FUSION PROTEIN WHICH CONSISTS OF A RECEPTOR-BINDING DOMAIN (RBD) OF CORONAVIRUS SARS-COV-2 SPIKE PROTEIN AND A MONOMERIC NON- GLYCOSYLATED FC-FRAGMENT OF HUMAN IGG1

Abstract

Variants of genetic constructions are discussed which encode a receptor-binding domain (RBD) of coronavirus SARS-CoV-2 spike protein fused with a monomeric Fc-fragment of human immunoglobulins. A cell line producing RBD-Fc is established. High titers of anti-RBD antibodies and virus-neutralizing antibodies are obtained upon mice immunization with the purified RBD-Fc.